Table 6.

Incidence of CMV viremia and disease

	G-CSF	IV plerixafor	Risk difference (95% CI)
CMV viremia ≥10 000 copies/mL	62% (43/69)	15% (3/20)	47% (23%, 69%)
CMV disease with preemptive treatment	6% (4/69)	5% (1/20)	0.8% (−24%, 25%)